Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high <scp>PD‐L1</scp>-Reference-Cited by-同舟云学术

Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1

Published:2022-04-30 Issue:11 Volume:13 Page:1611-1618
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Masuda Takeshi¹^ORCID,Fujitaka Kazunori¹,Suzuki Tomoko²,Hamai Kosuke³^ORCID,Matsumoto Naoko⁴,Matsumura Mirai¹³,Isoyama Shoko¹³,Ueno Sayaka³,Mito Mineyo⁵,Yamaguchi Kakuhiro¹^ORCID,Sakamoto Shinjiro¹,Kawano Reo⁶,Masuda Ken⁷,Nishino Ryohei⁸,Ishikawa Nobuhisa³^ORCID,Yamasaki Masahiro⁴,Hattori Noboru¹

Affiliation:

1. Department of Respiratory Medicine Hiroshima University Hospital Hiroshima Japan

2. Department of Respiratory Internal Medicine JA Onomichi General Hospital Hiroshima Japan

3. Department of Respiratory Medicine Hiroshima Prefectural Hospital Hiroshima Japan

4. Department of Respiratory Internal Medicine Hiroshima Red Cross Hospital & Atomic‐bomb Survivors Hospital Hiroshima Japan

5. Department of Respiratory Internal Medicine Kure Medical Center Hiroshima Japan

6. Department of Clinical Research Center in Hiroshima Hiroshima University Hospital Hiroshima Japan

7. Department of Respiratory Internal Medicine Hiroshima City Hiroshima Citizens Hospital Hiroshima Japan

8. Department of Respiratory Internal Medicine Hiroshima City Asa Citizens Hospital Hiroshima Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14428

Reference28 articles.

1. Cancer Statistics, 2021

2. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

4. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

5. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis;Frontiers in Immunology;2023-07-13

2. Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis;Frontiers in Oncology;2023-04-19

3. Lung Immunotherapy in the Elderly with NSCLC – the Who, the What, and the When;Interdisciplinary Cancer Research;2023